Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Disease Introduction
2.2 Symptoms
2.3 Epidemiology
2.4 Etiology
2.5 Pathophysiology
2.5.1 Diagnosis Rating Scales
2.5.2 DSM-5 Criteria for ADHD
2.5.3 ICD-10 Criteria for Hyperkinetic Disorder
2.6 Treatment
2.6.1 Treatment Algorithm
3 Marketed Products
3.1 Stimulant Drugs
3.1.1 Adderall XR – Shire
3.1.2 Concerta – Janssen Pharmaceuticals
3.1.3 Daytrana – Noven Pharmaceuticals
3.1.4 Focalin XR – Novartis
3.1.5 Ritalin LA – Novartis
3.1.6 Provigil – Teva Pharmaceutical
3.1.7 Quillivant XR– Pfizer Pharmaceuticals
3.1.8 Vyvanse – Shire
3.2 Non-stimulant Drugs
3.2.1 Strattera – Eli Lilly
3.2.2 Intuniv – Shire
3.2.3 Kapvay – Concordia Pharmaceuticals
3.3 Comparative Efficacy and Safety
4 ADHD Pipeline
4.1 Overview
4.2 Mechanisms of Action in the Pipeline
4.3 Clinical Trials
4.3.1 Attrition Rate
4.3.2 Clinical Trial Duration
4.3.3 Clinical Trial Size
4.3.4 Comparative Clinical Trial Metrics Analysis
4.3.5 SHP465 – Shire
4.3.6 NT-0202 – Neos Therapeutics
4.3.7 Edivoxetine – Eli Lilly
4.3.8 NWP09 – Pfizer
4.3.9 NT-0102 – Neos Therapeutics
4.3.10 Metadoxine ER – Alcobra
4.3.11 SPN-812 – Supernus Pharmaceuticals
4.3.12 Dextroamphetamine Transdermal – Noven Pharmaceuticals
4.4 Comparative Efficacy and Safety
5 Market Forecast to 2020
5.1 Global Market
5.2 North America
5.2.1 Treatment Usage Patterns
5.2.2 Annual Cost of Treatment
5.2.3 Market Size
5.3 Leading Five EU Countries (EU5)
5.3.1 Treatment Usage Patterns
5.3.2 Annual Cost of Treatment
5.3.3 Market Size
5.4 Japan
5.4.1 Treatment Usage Patterns
5.4.2 Annual Cost of Treatment
5.4.3 Market Size
5.5 Drivers and Barriers
5.5.1 Drivers
5.5.2 Barriers
6 Deals and Strategic Consolidations
6.1 Overview
6.2 Co-development Deals
7 Appendix
7.1 Market Definition
7.2 Abbreviations
7.3 References
7.4 Research Methodology
7.4.1 Secondary Research
7.4.2 Marketed Product Profiles
7.4.3 Late-Stage Pipeline Candidates
7.4.4 Comparative Efficacy and Safety Heat Map for Marketed and Pipeline Products
7.4.5 Product Competitiveness Framework
7.4.6 Pipeline Analysis
7.4.7 Forecasting Model
7.4.8 Deals Data Analysis
7.5 Contact Us
7.6 Disclaimer